Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.
But Why Tho? on MSNOpinion
'Pluribus' is the anti–Star Trek
In Pluribus, the frontier isn’t space but Earth, raising the question of whether humanity has earned the right to boldly ...
The EU project ENDOTARGET aims to improve the quality of life of people with rheumatic diseases. As part of a population cohort analysis, preliminary analyses provided initial insights into the ...
Extracellular vesicles (EVs), including exosomes, microvesicles, apoptotic bodies, and many other EV subtypes, have emerged ...
Mounting evidence from research on nematodes to mice indicate that a father's environment, such as what he eats or if he is ...
The last summer Olympics were full of queer couples, and the Winter Games are going to be no different. So far, we have four ...
CDK2-mediated TBK1 degradation via Dtx4 represents a previously unrecognized regulatory mechanism that modulates antiviral immunity in fish.
Validated next-generation sequencing soon will become necessary in ensuring the safety and efficacy of cell and gene ...
Validated clinical efficacy and scalable manufacturing propel exosomes from research discovery to commercial therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results